RxDoctor Payments Data

Firaz Hosein, DO

Hospice and Palliative Medicine · Lighthouse Point, FLNPI 1972505410

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $142 and has fallen 86.4% since, to $19 in 2024.

$298in general payments, 2019–2025

Across 12 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$57
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$46
  • Neuronetics, Inc.$46
  • E.r. Squibb & Sons, L.L.C.$40
  • Johnson & Johnson$37
  • Sunovion Pharmaceuticals Inc.$28
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$298 in reported general payments places this provider in the 80th percentile of 177 hospice and palliative medicine providers in Florida.

See all hospice and palliative medicine providers in Florida

Medicare billing

Part B allowed, 2024
$145,506
Medicare patients
318
Services billed
1,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$23,384
Clozapine24$10,235
Chlorpromazine Hcl24$8,786
RelistorMethylnaltrexone Bromide20$7,902
Levetiracetam109$7,549
MyrbetriqMirabegron14$7,481
Divalproex Sodium91$6,513
Risperidone116$6,465
GemtesaVibegron11$5,805
Ziprasidone Hcl24$3,982
Aripiprazole48$3,150
Atorvastatin Calcium211$2,983
Levothyroxine Sodium235$2,961
Trifluoperazine Hcl45$2,823
Carbamazepine ErCarbamazepine12$2,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$23,38441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 hospice and palliative medicine providers in Florida.

Other hospice and palliative medicine in Lighthouse Point

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →